{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+chloride%29+infusion&page=4",
    "query": {
      "intervention": "Placebo (0.9% Sodium chloride) infusion",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 416,
    "total_pages": 42,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+chloride%29+infusion&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%280.9%25+Sodium+chloride%29+infusion&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T07:06:44.538Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03867084",
      "title": "Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 959,
      "start_date": "2019-05-28",
      "completion_date": "2025-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-12T07:06:44.538Z",
      "location_count": 24,
      "location_summary": "Gilbert, Arizona • Tucson, Arizona • Duarte, California + 18 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03867084"
    },
    {
      "nct_id": "NCT02325414",
      "title": "Prevention of Bone Loss After Acute SCI by Zoledronic Acid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Spinal Cord Injury",
        "Acute Spinal Cord Injury",
        "Bone Loss",
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2015-02",
      "completion_date": "2020-08-25",
      "has_results": true,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-10-12T07:06:44.538Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02325414"
    },
    {
      "nct_id": "NCT01960348",
      "title": "APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "TTR-mediated Amyloidosis",
        "Amyloidosis, Hereditary",
        "Amyloid Neuropathies, Familial",
        "Familial Amyloid Polyneuropathies",
        "Amyloid Neuropathies",
        "Amyloidosis, Hereditary, Transthyretin-Related"
      ],
      "interventions": [
        {
          "name": "patisiran (ALN-TTR02)",
          "type": "DRUG"
        },
        {
          "name": "Sterile Normal Saline (0.9% NaCl)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 225,
      "start_date": "2013-11",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2024-04-22",
      "last_synced_at": "2026-10-12T07:06:44.538Z",
      "location_count": 13,
      "location_summary": "La Mesa, California • Orange, California • Denver, Colorado + 9 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01960348"
    },
    {
      "nct_id": "NCT02222714",
      "title": "Safety Evaluation of 3K3A-APC in Ischemic Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "3K3A-APC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "ZZ Biotech, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 110,
      "start_date": "2014-10",
      "completion_date": "2017-06-29",
      "has_results": true,
      "last_update_posted_date": "2018-11-08",
      "last_synced_at": "2026-10-12T07:06:44.538Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02222714"
    },
    {
      "nct_id": "NCT00623363",
      "title": "Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "piclozotan",
          "type": "DRUG"
        },
        {
          "name": "0.9% sodium chloride (normal saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2007-07-13",
      "completion_date": "2008-07-17",
      "has_results": true,
      "last_update_posted_date": "2021-03-11",
      "last_synced_at": "2026-10-12T07:06:44.538Z",
      "location_count": 5,
      "location_summary": "Fountain Valley, California • Tampa, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00623363"
    },
    {
      "nct_id": "NCT07246863",
      "title": "Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Non-Squamous Non-Small Cell Lung Cancer",
        "Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Visugromab RDE (recommended dose for expansion)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Visugromab 6mg/kg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Saline Infusion",
          "type": "OTHER"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "CatalYm GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2025-10-07",
      "completion_date": "2031-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-12T07:06:44.538Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mineola",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07246863"
    },
    {
      "nct_id": "NCT00843193",
      "title": "Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "INTRAVENOUS GSK679586",
          "type": "DRUG"
        },
        {
          "name": "INTRAVENOUS PLACEBO",
          "type": "DRUG"
        },
        {
          "name": "FLUTICASONE PROPIONATE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 198,
      "start_date": "2008-12-09",
      "completion_date": "2010-07-25",
      "has_results": true,
      "last_update_posted_date": "2017-12-12",
      "last_synced_at": "2026-10-12T07:06:44.538Z",
      "location_count": 6,
      "location_summary": "Medford, Oregon • Portland, Oregon • Pittsburgh, Pennsylvania + 3 more",
      "locations": [
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Orangeburg",
          "state": "South Carolina"
        },
        {
          "city": "Boerne",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00843193"
    },
    {
      "nct_id": "NCT04468659",
      "title": "AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Preclinical Alzheimer's Disease",
        "Early Preclinical Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Lecanemab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 1400,
      "start_date": "2020-07-14",
      "completion_date": "2031-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-12T07:06:44.538Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04468659"
    },
    {
      "nct_id": "NCT01083615",
      "title": "A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Castrate-Resistant Prostate Cancer",
        "Hormone Refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "custirsen sodium",
          "type": "DRUG"
        },
        {
          "name": "isotonic, 0.9% sodium chloride",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "cabazitaxel",
          "type": "DRUG"
        },
        {
          "name": "prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Achieve Life Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "MALE",
        "summary": "18 Years to 99 Years · Male only"
      },
      "enrollment_count": 14,
      "start_date": "2010-03",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2016-10-12",
      "last_synced_at": "2026-10-12T07:06:44.538Z",
      "location_count": 20,
      "location_summary": "La Verne, California • Fort Lauderdale, Florida • Tampa, Florida + 17 more",
      "locations": [
        {
          "city": "La Verne",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01083615"
    },
    {
      "nct_id": "NCT01954082",
      "title": "Inositol to Reduce Retinopathy of Prematurity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Retinopathy of Prematurity (ROP)"
      ],
      "interventions": [
        {
          "name": "myo-Inositol 5% Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NICHD Neonatal Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Hours",
        "maximum_age": "72 Hours",
        "sex": "ALL",
        "summary": "12 Hours to 72 Hours"
      },
      "enrollment_count": 638,
      "start_date": "2014-04-17",
      "completion_date": "2016-12-31",
      "has_results": true,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-10-12T07:06:44.538Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01954082"
    }
  ]
}